<?xml version="1.0" encoding="utf-8"?>
<!-- generator="FeedCreator 1.7.2-ppt (info@mypapit.net)" -->
<feed xmlns="http://www.w3.org/2005/Atom">
    <title>Reuters News Articles By Jeffrey Goldfarb</title>
    <subtitle>Find the latest breaking news from around the world on Reuters.com, including news articles on politics, technology, business, entertainment and more.</subtitle>
    <link rel="alternate" type="text/html" href="http://www.reuters.com/"/>
    <id>http://www.reuters.com/</id>
    <updated>2009-11-26T10:09:14+01:00</updated>
    <generator>FeedCreator 1.7.2-ppt (info@mypapit.net)</generator>
<link rel="self" type="application/atom+xml" href="http://blogs.reuters.com/wp-content/plugins/reuters-author-news-rss-feed/feed.php?author=Jeffrey Goldfarb" />
    <entry>
        <title>UPDATE 1-Private equity firms to be asked to open up</title>
        <link rel="alternate" type="text/html" href="http://www.reuters.com/article/governmentFilingsNews/idUSL199055020071119"/>
        <published>2007-11-19T12:05:53+01:00</published>
        <updated>2007-11-19T12:05:53+01:00</updated>
        <id>http://www.reuters.com/article/governmentFilingsNews/idUSL199055020071119</id>
        <author>
            <name>Jeffrey Goldfarb</name>
        </author>
        <summary> LONDON, Nov 19 (Reuters) - The private equity industry,
which employs about 8 percent of Britons working in the private
sector, will be asked to become more transparent to shed its
image of secretiveness, a report is expected to say on Tuesday.</summary>
    </entry>
    <entry>
        <title>Private equity firms to be asked to open up</title>
        <link rel="alternate" type="text/html" href="http://www.reuters.com/article/mergersNews/idUSL18285920071119"/>
        <published>2007-11-19T10:49:22+01:00</published>
        <updated>2007-11-19T10:49:22+01:00</updated>
        <id>http://www.reuters.com/article/mergersNews/idUSL18285920071119</id>
        <author>
            <name>Jeffrey Goldfarb</name>
        </author>
        <summary> LONDON, Nov 19 (Reuters) - The private equity industry,
employer of about 8 percent of Britons working in the private
sector, will be asked to become more transparent to shed its
image of secretiveness, a report is expected to say on Tuesday.</summary>
    </entry>
    <entry>
        <title>Romania pay-TV firm RCS &amp; RDS pulls IPO</title>
        <link rel="alternate" type="text/html" href="http://www.reuters.com/article/newIssuesNews/idUSL06231720071106"/>
        <published>2007-11-06T11:22:42+01:00</published>
        <updated>2007-11-06T11:22:42+01:00</updated>
        <id>http://www.reuters.com/article/newIssuesNews/idUSL06231720071106</id>
        <author>
            <name>Jeffrey Goldfarb</name>
        </author>
        <summary> LONDON, Nov 6 (Reuters) - Romania-based satellite TV, phone
and Internet company RCS &amp;amp; RDS &amp;lt;RCSSq.L&amp;gt; on Tuesday withdrew an
IPO of up to $540 million, citing market conditions.</summary>
    </entry>
    <entry>
        <title>Dubai fund buys UK's Alliance Medical</title>
        <link rel="alternate" type="text/html" href="http://www.reuters.com/article/innovationNews/idUSL0533248520071105"/>
        <published>2007-11-05T17:45:37+01:00</published>
        <updated>2007-11-05T17:45:37+01:00</updated>
        <id>http://www.reuters.com/article/innovationNews/idUSL0533248520071105</id>
        <author>
            <name>Jeffrey Goldfarb</name>
        </author>
        <summary>LONDON (Reuters) - Dubai International Capital has bought Alliance Medical for 600 million pounds ($1.25 billion), with plans to expand one of Europe's largest MRI and CT scan services provider into the Middle East and Asia.</summary>
    </entry>
    <entry>
        <title>Mid Europa readies region's largest buyout fund</title>
        <link rel="alternate" type="text/html" href="http://www.reuters.com/article/summitNews/idUSL1672538520071017"/>
        <published>2007-10-17T12:00:55+01:00</published>
        <updated>2007-10-17T12:00:55+01:00</updated>
        <id>http://www.reuters.com/article/summitNews/idUSL1672538520071017</id>
        <author>
            <name>Jeffrey Goldfarb</name>
        </author>
        <summary>VIENNA (Reuters) - Private equity firm Mid Europa Partners is set to close a 1.5 billion euro ($2.1 billion) fund, ahead of its original goal and by far the largest devoted to the central European region, its managing partner said on Tuesday.</summary>
    </entry>
    <entry>
        <title>Pfizer, Sanofi, J&amp;J may be among Biogen bidders</title>
        <link rel="alternate" type="text/html" href="http://www.reuters.com/article/health-SP/idUSN1537945120071015"/>
        <published>2007-10-15T20:15:18+01:00</published>
        <updated>2007-10-15T20:15:18+01:00</updated>
        <id>http://www.reuters.com/article/health-SP/idUSN1537945120071015</id>
        <author>
            <name>Jeffrey Goldfarb</name>
        </author>
        <summary>    LONDON/BOSTON, Oct 15 (Reuters) - Biogen Idec Inc &amp;lt;BIIB.O&amp;gt;, which has put itself up for sale, may get bids of around $25-30 billion from several of the world's top drugmakers keen to expand in the hot area of biotech medicine.</summary>
    </entry>
    <entry>
        <title>Buyout firm slams &quot;half-baked&quot; UK policies</title>
        <link rel="alternate" type="text/html" href="http://www.reuters.com/article/summitNews/idUSL1653033120071016"/>
        <published>2007-10-16T16:52:55+01:00</published>
        <updated>2007-10-16T16:52:55+01:00</updated>
        <id>http://www.reuters.com/article/summitNews/idUSL1653033120071016</id>
        <author>
            <name>Jeffrey Goldfarb</name>
        </author>
        <summary>VIENNA (Reuters) - Buyout firm Mid Europa Partners said more &quot;half-baked&quot; policies from the British government in reaction to a political and union outcry against private equity could prompt it to leave the country.</summary>
    </entry>
    <entry>
        <title>Pfizer, Sanofi, J&amp;J may be among Biogen bidders</title>
        <link rel="alternate" type="text/html" href="http://www.reuters.com/article/businessNews/idUSL1527076720071015"/>
        <published>2007-10-15T20:16:40+01:00</published>
        <updated>2007-10-15T20:16:40+01:00</updated>
        <id>http://www.reuters.com/article/businessNews/idUSL1527076720071015</id>
        <author>
            <name>Jeffrey Goldfarb</name>
        </author>
        <summary>LONDON/BOSTON (Reuters) - Biogen Idec Inc &amp;lt;BIIB.O&amp;gt;, which has put itself up for sale, may get bids of around $25-30 billion from several of the world's top drugmakers keen to expand in the hot area of biotech medicine.</summary>
    </entry>
    <entry>
        <title>UPDATE 1-Pfizer, Sanofi, J&amp;J may be among Biogen bidders</title>
        <link rel="alternate" type="text/html" href="http://www.reuters.com/article/mergersNews/idUSN1537945120071015"/>
        <published>2007-10-15T20:15:00+01:00</published>
        <updated>2007-10-15T20:15:00+01:00</updated>
        <id>http://www.reuters.com/article/mergersNews/idUSN1537945120071015</id>
        <author>
            <name>Jeffrey Goldfarb</name>
        </author>
        <summary> LONDON/BOSTON, Oct 15 (Reuters) - Biogen Idec Inc &amp;lt;BIIB.O&amp;gt;,
which has put itself up for sale, may get bids of around $25-30
billion from several of the world's top drugmakers keen to
expand in the hot area of biotech medicine.</summary>
    </entry>
    <entry>
        <title>Not enough C. Europe deals for buyers: banker</title>
        <link rel="alternate" type="text/html" href="http://www.reuters.com/article/CentralEuropeanInvestment07/idUSL1547338520071015"/>
        <published>2007-10-15T18:27:39+01:00</published>
        <updated>2007-10-15T18:27:39+01:00</updated>
        <id>http://www.reuters.com/article/CentralEuropeanInvestment07/idUSL1547338520071015</id>
        <author>
            <name>Jeffrey Goldfarb</name>
        </author>
        <summary>VIENNA (Reuters) - Much of central and eastern Europe is no longer considered an emerging market by corporate and private equity buyers, but it will be another five years before the area sees a steady flow of bigger deals, an investment banker focused ...</summary>
    </entry>
</feed>
